[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352555-105":59,"doc-detail-352555-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","implications-of-homologous-recombination-deficiency-for-neoadjuvant-platinum-based-chemotherapy-in-pancreatic-cancer-a-narrative-review","Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer: A Narrative Review","","Homologous recombination deficiency (HRD) is evaluated as a predictive biomarker to guide neoadjuvant platinum-based chemotherapy in pancreatic ductal adenocarcinoma (PDAC), a malignancy with poor 5-year survival (~13%) and frequent distant recurrence. Neoadjuvant platinum regimens may improve resectability and survival, yet toxicities, variable responses, and tumor progression can delay curative surgery. HR-pathway alterations are reported in 3.0–19.5% of PDAC and can sensitize tumors to platinum therapy. Evidence suggests HRD-associated PDAC may achieve improved downstaging, resectability, and outcomes, while prospective studies remain needed.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/implications-of-homologous-recombination-deficiency-for-neoadjuvant-platinum-based-chemotherapy-in-pancreatic-cancer-a-narrative-review/352555/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/implications-of-homologous-recombination-deficiency-for-neoadjuvant-platinum-based-chemotherapy-in-pancreatic-cancer-a-narrative-review/352555.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"What is the paper’s main conclusion about HRD testing?","Question",{"text":113,"@type":114},"Homologous recombination deficiency is presented as a promising biomarker to guide selection for neoadjuvant platinum-based chemotherapy. Incorporating HRD testing into treatment schemes may enable a more personalized approach aligned with precision oncology for early-stage PDAC.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},352555,1790168145,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Ann Surg Oncol (2026) 33:3583–3592  \n[https://doi.org/10.1245/s10434-025-19056-0](https://doi.org/10.1245/s10434-025-19056-0)  \nREVIEW ARTICLE – PANCREATIC TUMORS  \nImplications of Homologous Recombination Deficiency for Neoadjuvant Platinum‑Based Chemotherapy in Pancreatic Cancer: A Narrative Review  \nLuigi Liguori, MD1,2, Marco Ventin, MD1, Giulia Cattaneo, PhD1, Liti Zhang, MD1, Arsen Osipov, MD3, Francesco Sabbatino, MD, PhD2, and Cristina R. Ferrone, MD1,3  \n1Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA; 2Department of Medicine, Surgery and Dentistry“Scuola Medica Salernitana”, University of Salerno, Salerno, Italy; 3Department of Medical Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA  \nABSTRACT  \nBackground. Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, with a 5 year survival rate of approximately 13% . Survival is extended for the few patients who undergo surgical resection with curative intent, whereas most patients succumb to distant disease recurrence. Neoadjuvant platinum-based chemotherapy has emerged as a promising strategy to improve resectability rates and survival outcomes for PDAC patients. However, treatment-related toxicities, unpredictable clinical responses, and associated risk of tumor progression during neoadjuvant therapy may delay or preclude curative resection.As a result, predictive biomarkers are needed to identify patients most likely to benefit from neoadjuvant platinum-based chemotherapy.  \nDiscussion. Alterations in the homologous recombination (HR) DNA repair pathway are reported in 3.0–19.5% of PDAC patients. These types of alterations can sensitize tumors to platinum-based chemotherapy in PDAC as well as other cancers including ovarian, colorectal, and prostate cancers. Retrospective and prospective studies in locally advanced/metastatic PDAC demonstrate higher response rates and longer survival outcomes among HR-deficient  \nLuigi Liguori and Marco Ventin authors share first authorship.  \n© The Author(s) 2026  \nFirst Received: 28 October 2025  \nAccepted: 25 December 2025  \nPublished online: 31 January 2026  \nC. R. Ferrone, MD  \ne-mail: [cristina.ferrone@cshs.org](cristina.ferrone@cshs.org)  \n(HRD) patients receiving platinum-based chemotherapy. A growing body of evidence in the neoadjuvant setting suggests a potential benefit for HRD-PDAC patients in terms of enhanced tumor downstaging, higher resectability, and improved survival outcomes compared with HR-proficient patients. However, prospective ad hoc studies are still warranted to confirm these findings  \nConclusions. Homologous recombination deficiency represents a promising biomarker to guide patient selection for neoadjuvant platinum-based chemotherapy in PDAC. Incorporation of HR deficiency-testing into neoadjuvant treatment schemes will enable a more personalized therapeutic approach, supporting the implementation of precision oncology for early-stage PDAC patients.  \nKeywords BRCA1/2 · HRD · Neoadjuvant · PDAC · Platinum  \nPancreatic ductal adenocarcinoma (PDAC) is among the most aggressive malignancies, with a 5 year survival rate of approximately 13% . Globally, the incidence of PDAC is rising, making it the third leading cause of cancer-related deaths in United States.1  \nThe majority of patients present with locally advanced or metastatic disease, and only a limited proportion (10–15%) of patients are eligible for surgical resection at the time of diagnosis.2 Even in the case of localized disease, surgery alone is often not sufficient because PDAC is an aggressive systemic disease, and available chemotherapies to date are not sufficiently effective.  \nThe phase 3 PRODIGE24 trial demonstrated improved overall survival (OS) for adjuvant chemotherapy combined  \nwith fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) compared with gemcitabine for resected PDAC patients.3 However, the 5 year disease-free survival ","cbCairxeLnYb5tu9","https://ap.wps.com/l/cbCairxeLnYb5tu9","pdf",590856,"English","# Background\n## Neoadjuvant platinum-based chemotherapy and clinical challenges\n# Discussion\n## Homologous recombination DNA repair alterations and platinum sensitivity\n## Evidence from locally advanced/metastatic PDAC studies\n# Conclusions\n## HRD as a biomarker for patient selection","[{\"question\":\"What is the paper’s main conclusion about HRD testing?\",\"answer\":\"Homologous recombination deficiency is presented as a promising biomarker to guide selection for neoadjuvant platinum-based chemotherapy. Incorporating HRD testing into treatment schemes may enable a more personalized approach aligned with precision oncology for early-stage PDAC.\"}]","Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer: A Narrative Review | PDF",1790100240,25]